The aberrant accumulation of aggregated beta-amyloid peptides (Abeta) as plaques is a hallmark of Alzheimer's disease (AD) neuropathology and reduction of Abeta has become a leading direction of emerging experimental therapies for the disease. The mechanism(s) whereby Abeta is involved in the pathophysiology of the disease remain(s) poorly understood. Dr Gunnar Gouras' laboratory gathers evidence linking intraneuronal Abeta accumulation to the development of synaptic pathology and plaques in AD.
Intraneuronal beta-amyloid accumulation in Alzheimer's disease
Area of expertise:
Dr Gunnar Gouras, Wallenberg Neuroscience Center, Lund (Sweden)